Cargando…
Evaluation of Medication Package Inserts in Iran
OBJECTIVE: Package inserts (PIs) provide information for the safe and effective use of medication. There is no study on the evaluation of PIs in Iran. The purpose of this study was to evaluate the completeness of PIs supplied with the 100 top-selling medications in Iran. METHODS: This cross-sectiona...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636423/ https://www.ncbi.nlm.nih.gov/pubmed/31367638 http://dx.doi.org/10.4103/jrpp.JRPP_18_32 |
_version_ | 1783436058529103872 |
---|---|
author | Khamas, Shahriyar Shahbazi Jafari, Atefeh Zarif-Yeganeh, Morvarid Taghvaye-Masoumi, Hamidreza |
author_facet | Khamas, Shahriyar Shahbazi Jafari, Atefeh Zarif-Yeganeh, Morvarid Taghvaye-Masoumi, Hamidreza |
author_sort | Khamas, Shahriyar Shahbazi |
collection | PubMed |
description | OBJECTIVE: Package inserts (PIs) provide information for the safe and effective use of medication. There is no study on the evaluation of PIs in Iran. The purpose of this study was to evaluate the completeness of PIs supplied with the 100 top-selling medications in Iran. METHODS: This cross-sectional observational study was conducted during 3 weeks in January 2017. One hundred medications were chosen from a list supplied by the Iran Food and Drug Administration (IFDA). The PIs were assessed for the presentation and completeness of quality criteria, which was consisted of two parts. The first part was the criteria required by the IFDA, mentioned in Chapter 16 of the Pharmaceutical Regulations and Instructions provided by the IFDA. The second part of the criteria was defined according to the critical comments of clinical and industrial pharmacists. FINDINGS: Thirty-seven out of 100 medications included no PIs. None of the PIs met all the criteria required by the IFDA. The highest score for completeness was 18 out of 21 (85.7%). Medication name, description, and adverse reaction were mentioned in all PIs. Other items such as patient counseling information (98%), warnings (95.2%), precautions (95.2%), pregnancy/lactation (95%), and storage condition (90.5%) have been mentioned in a high percentage of PIs. CONCLUSION: PIs have improved in recent years in Iran, but there is an absolute need for more accurate and up-to-date information. The IFDA should supervise pharmaceutical companies more strictly in this regard and should revise its regulations requiring PIs to conform to the FDA regulations. |
format | Online Article Text |
id | pubmed-6636423 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-66364232019-07-31 Evaluation of Medication Package Inserts in Iran Khamas, Shahriyar Shahbazi Jafari, Atefeh Zarif-Yeganeh, Morvarid Taghvaye-Masoumi, Hamidreza J Res Pharm Pract Original Article OBJECTIVE: Package inserts (PIs) provide information for the safe and effective use of medication. There is no study on the evaluation of PIs in Iran. The purpose of this study was to evaluate the completeness of PIs supplied with the 100 top-selling medications in Iran. METHODS: This cross-sectional observational study was conducted during 3 weeks in January 2017. One hundred medications were chosen from a list supplied by the Iran Food and Drug Administration (IFDA). The PIs were assessed for the presentation and completeness of quality criteria, which was consisted of two parts. The first part was the criteria required by the IFDA, mentioned in Chapter 16 of the Pharmaceutical Regulations and Instructions provided by the IFDA. The second part of the criteria was defined according to the critical comments of clinical and industrial pharmacists. FINDINGS: Thirty-seven out of 100 medications included no PIs. None of the PIs met all the criteria required by the IFDA. The highest score for completeness was 18 out of 21 (85.7%). Medication name, description, and adverse reaction were mentioned in all PIs. Other items such as patient counseling information (98%), warnings (95.2%), precautions (95.2%), pregnancy/lactation (95%), and storage condition (90.5%) have been mentioned in a high percentage of PIs. CONCLUSION: PIs have improved in recent years in Iran, but there is an absolute need for more accurate and up-to-date information. The IFDA should supervise pharmaceutical companies more strictly in this regard and should revise its regulations requiring PIs to conform to the FDA regulations. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6636423/ /pubmed/31367638 http://dx.doi.org/10.4103/jrpp.JRPP_18_32 Text en Copyright: © 2019 Journal of Research in Pharmacy Practice http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Khamas, Shahriyar Shahbazi Jafari, Atefeh Zarif-Yeganeh, Morvarid Taghvaye-Masoumi, Hamidreza Evaluation of Medication Package Inserts in Iran |
title | Evaluation of Medication Package Inserts in Iran |
title_full | Evaluation of Medication Package Inserts in Iran |
title_fullStr | Evaluation of Medication Package Inserts in Iran |
title_full_unstemmed | Evaluation of Medication Package Inserts in Iran |
title_short | Evaluation of Medication Package Inserts in Iran |
title_sort | evaluation of medication package inserts in iran |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636423/ https://www.ncbi.nlm.nih.gov/pubmed/31367638 http://dx.doi.org/10.4103/jrpp.JRPP_18_32 |
work_keys_str_mv | AT khamasshahriyarshahbazi evaluationofmedicationpackageinsertsiniran AT jafariatefeh evaluationofmedicationpackageinsertsiniran AT zarifyeganehmorvarid evaluationofmedicationpackageinsertsiniran AT taghvayemasoumihamidreza evaluationofmedicationpackageinsertsiniran |